Skin: First-line metastatic melanoma (CheckMate 067)
Free question published 15 November 2026
A 55-year-old man presents with newly diagnosed unresectable stage IV BRAF wild-type cutaneous melanoma. He has an excellent performance status, normal organ function and no autoimmune disease, and prioritises the best chance of long-term survival. Citing CheckMate 067, which first-line systemic therapy is most appropriate?
- ASingle-agent vemurafenib
- BCombination nivolumab plus ipilimumab
- CDacarbazine chemotherapy
- DDabrafenib plus trametinib
- ESingle-agent ipilimumab checkpoint inhibitor monotherapy
Why B is correct
CheckMate 067 showed that combination nivolumab plus ipilimumab gave the highest 5-year overall survival (52%) compared with nivolumab alone (44%) and ipilimumab alone (26%), establishing combination immune checkpoint inhibition as a first-line standard for advanced melanoma irrespective of BRAF status. For a fit patient seeking the best long-term survival, combination therapy is the most appropriate first-line option.
And why the others are not
- AIncorrect: vemurafenib is a BRAF inhibitor with no role in BRAF wild-type disease.
- CIncorrect: dacarbazine is markedly inferior to modern immunotherapy and is not a preferred first-line option.
- DIncorrect: dabrafenib plus trametinib requires a BRAF V600 mutation, which this BRAF wild-type patient does not have.
- EIncorrect: single-agent ipilimumab gave the lowest 5-year survival (26%) of the three arms.
Source CheckMate 067 - Combined nivolumab and ipilimumab in advanced melanoma — Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535-1546.
More free skin questions
- Skin: Adjuvant immunotherapy stage III (CheckMate 238) · 04 November 2026
- Skin: Sentinel node biopsy threshold by Breslow thickness · 24 October 2026
- Skin: Wide local excision margin for thin melanoma · 13 October 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing